Although targeting the NLRP3 inflammasome seems like a promising strategy for PD treatment, the lack of information on how the activation of the NLRP3 inflammasome can directly affect the survival of dopaminergic neurons has slowed down the progress in this direction (Haque et al., 2020). Here, NLRP3 is linked to Parkinson disease.